Genmab A/S (NASDAQ:GMAB) Rating Increased to Outperform at Leerink Partners

Leerink Partners upgraded shares of Genmab A/S (NASDAQ:GMAB) from a market perform rating to an outperform rating in a research report sent to investors on Thursday, Marketbeat reports. They currently have $27.00 price objective on the stock.

GMAB has been the subject of a number of other reports. BMO Capital Markets restated an “outperform” rating and set a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research note on Thursday, January 23rd. Finally, Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $42.17.

Genmab A/S Stock Up 6.2 %

Shares of NASDAQ GMAB opened at $20.92 on Thursday. The business has a fifty day simple moving average of $20.68 and a two-hundred day simple moving average of $23.21. The firm has a market cap of $13.84 billion, a PE ratio of 20.31, a price-to-earnings-growth ratio of 0.54 and a beta of 0.96. Genmab A/S has a twelve month low of $18.64 and a twelve month high of $31.88.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. On average, research analysts expect that Genmab A/S will post 1.25 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Ritholtz Wealth Management acquired a new position in shares of Genmab A/S in the third quarter valued at about $314,000. Creative Planning increased its holdings in shares of Genmab A/S by 136.3% in the third quarter. Creative Planning now owns 47,422 shares of the company’s stock valued at $1,156,000 after purchasing an additional 27,353 shares during the period. Bleakley Financial Group LLC grew its holdings in Genmab A/S by 7.7% during the third quarter. Bleakley Financial Group LLC now owns 30,732 shares of the company’s stock worth $749,000 after acquiring an additional 2,196 shares during the period. Blue Trust Inc. grew its holdings in Genmab A/S by 892.0% during the third quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock worth $108,000 after acquiring an additional 3,880 shares during the period. Finally, Raymond James & Associates grew its holdings in Genmab A/S by 2.2% during the third quarter. Raymond James & Associates now owns 169,747 shares of the company’s stock worth $4,138,000 after acquiring an additional 3,598 shares during the period. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.